Tous Actualités
Suivre
Abonner Epigenomics AG

Epigenomics AG

EANS-Adhoc: Ad Hoc Announcement pursuant of §15 WpHG (German Securities Trading Act): Epigenomics AG: Strategic Partner Abbott Launches Colorectal Cancer Blood Test in Europe and Asia/Pacific

  ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
  adhoc with the aim of a Europe-wide distribution. The issuer is solely
  responsible for the content of this announcement.
Licensing Agreements/Molecular diagnostics
21.12.2009
Berlin, December 21, 2009 - Epigenomics AG (ISIN: DE000A0BVT96), a 
cancer molecular diagnostics company, informs that its strategic 
licensing and collaboration partner Abbott launched a molecular 
diagnostic blood test to aid in the diagnosis of colorectal cancer in
Europe and Asia/Pacific. The in vitro diagnostic test is based on 
Epigenomics´ proprietary biomarker Septin9. Abbott licensed the 
non-exclusive worldwide rights to Septin9 in September 2007. The in 
vitro diagnostic test is commercialized by Abbott under the brand 
name Abbott RealTime mS9 Colorectal Cancer Assay and is optimized for
Abbott´s RealTime system m2000. The launch triggers a milestone 
payment to Epigenomics. Going forward Epigenomics will participate in
the commercial success of the mS9 Colorectal Cancer Assay through 
royalties on product sales as well as certain sales-related 
milestones. With the launch Epigenomics continues executing its dual 
business model of non-exclusive licensing and direct 
commercialization of its cancer molecular diagnostic tests.
End of Ad hoc
Epigenomics legal disclaimers. This communication expressly or 
implicitly contains certain forward-looking statements concerning 
Epigenomics AG and its business. Such statements involve certain 
known and unknown risks, uncertainties and other factors which could 
cause the actual results, financial condition, performance or 
achievements of Epigenomics AG to be materially different from any 
future results, performance or achievements expressed or implied by 
such forward-looking statements. Epigenomics AG is providing this 
communication as of this date and does not undertake to update any 
forward- looking statements contained herein as a result of new 
information, future events or otherwise.
The information contained in this communication does not constitute 
nor imply an offer to sell or transfer any product, and no product 
based on this technology is currently available for sale in the 
United States. The analytical and clinical performance 
characteristics of any product based on this technology which may be 
sold at some future time in the U.S. have not been established.
end of announcement                               euro adhoc

Further inquiry note:

Epigenomics AG
Dr. Achim Plum
Sen. VP Corporate Development
Tel: +49 30 24345 368
achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade

Plus de actualités: Epigenomics AG
Plus de actualités: Epigenomics AG